Why will it never be known if convalescent plasma is effective for COVID-19

被引:13
作者
Rojas, Manuel [1 ]
Anaya, Juan-Manuel [1 ,2 ]
机构
[1] Univ Rosario, Ctr Autoimmune Dis Res CREA, Sch Med & Hlth Sci, Carrera 26-63-B-51, Bogota 110010, Colombia
[2] Clin Occidente, Bogota, Colombia
关键词
Coronavirus; COVID-19; SARS-Cov-2; Convalescent plasma; Clinical trials; Randomized;
D O I
10.1016/j.jtauto.2020.100069
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.
引用
收藏
页数:5
相关论文
共 27 条
  • [1] Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
    Agarwal, Anup
    Mukherjee, Aparna
    Kumar, Gunjan
    Chatterjee, Pranab
    Bhatnagar, Tarun
    Malhotra, Pankaj
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 371
  • [2] AlQahtani M., 2020, RANDOMIZED CONTROLLE, DOI [10.1101/2020.11.02.20224303, DOI 10.1101/2020.11.02.20224303]
  • [3] Avendano-Sola C., CONVALESCENT PLASMA
  • [4] Autoantibodies against type I IFNs in patients with life-threatening COVID-19
    Bastard, Paul
    Rosen, Lindsey B.
    Zhang, Qian
    Michailidis, Eleftherios
    Hoffmann, Hans-Heinrich
    Zhang, Yu
    Dorgham, Karim
    Philippot, Quentin
    Rosain, Jeremie
    Beziat, Vivien
    Manry, Jeremy
    Shaw, Elana
    Haljasmagi, Liis
    Peterson, Part
    Lorenzo, Lazaro
    Bizien, Lucy
    Trouillet-Assant, Sophie
    Dobbs, Kerry
    de Jesus, Adriana Almeida
    Belot, Alexandre
    Kallaste, Anne
    Catherinot, Emilie
    Tandjaoui-Lambiotte, Yacine
    Le Pen, Jeremie
    Kerner, Gaspard
    Bigio, Benedetta
    Seeleuthner, Yoann
    Yang, Rui
    Bolze, Alexandre
    Spaan, Andras N.
    Delmonte, Ottavia M.
    Abers, Michael S.
    Aiuti, Alessandro
    Casari, Giorgio
    Lampasona, Vito
    Piemonti, Lorenzo
    Ciceri, Fabio
    Bilguvar, Kaya
    Lifton, Richard P.
    Vasse, Marc
    Smadja, David M.
    Migaud, Melanie
    Hadjadj, Jerome
    Terrier, Benjamin
    Duffy, Darragh
    Quintana-Murci, Lluis
    van de Beek, Diederik
    Roussel, Lucie
    Vinh, Donald C.
    Tangye, Stuart G.
    [J]. SCIENCE, 2020, 370 (6515) : 423 - +
  • [5] Ebola virus convalescent blood products: Where we are now and where we may need to go
    Burnouf, Thierry
    Seghatchian, Jerard
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2014, 51 (02) : 120 - 125
  • [6] Day T, 2020, CURR BIOL, V30, pR849, DOI 10.1016/j.cub.2020.06.031
  • [7] Gharbharan A., CONVALESCENT PLASMA
  • [8] The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis
    Haley, M
    Retter, AS
    Fowler, D
    Gea-Banacloche, J
    O'Grady, NP
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (06) : E88 - E90
  • [9] Joyner M.J., EVIDENCE FAVOURING E
  • [10] Korber B, SPIKE MUTATION PIPEL